AMRA®MAsS Scan – Introducing an Objective Way to Help Clinicians Assess Muscle Health at ATC 2022
AMRA will be in Boston for the American Transplant Congress (ATC 2022) on June 4 – 8. We will be happy to…
Read MoreNews
AMRA Medical’s MRI-based body composition measurements used in Lilly’s SURPASS-3 tirzepatide sub-study
Eli Lilly and Company assessed the impact of tirzepatide, an investigational therapy for the treatment of type 2 diabetes, on liver fat,…
Read More
AMRA Webinar: The Patient Experience Using MRI in DMD Clinical Trials – “Shed Light Through MRI”
Join us – with patients, industry leaders and a patient advocacy group to learn how to implement a magnetic resonance imaging (MRI)…
Read More
AMRA Medical, Daiichi Sankyo and NCNP joint MRI-based muscle research accepted for poster presentation at 2022 MDA Conference
LINKÖPING, Sweden; March 14, 2022—AMRA’s recent research, performed in collaboration with Daiichi Sankyo and the National Center of Neurology and Psychiatry (NCNP)…
Read More
AMRA Medical’s MRI-Based Fat & Muscle Assessment Technology Approved for Clinical Use in US and Canada
LINKÖPING, Sweden; February 23, 2022—AMRA Medical, a ground-breaking digital health company and global leader in body composition analysis offering medical device and…
Read More
AMRA Medical’s MRI data provide a unique opportunity for Pfizer’s GWAS
LINKÖPING, Sweden; February 14, 2022—One of the goals of AMRA’s collaboration with Pfizer and UK Biobank is to help identify and validate…
Read More